Gastrointestinal

Neuroendocrine Tumors

Well Differentiated

Metastatic

1-3 Lung Nodules Amenable to Ablation

Operable

Inoperable

1st Line

Post 177Lu-DOTATATE

2nd Line

SARCOMA0058
Phase III Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Oligometastatic Tumors in the Lung
PI: Bedi
Sponsor: NeuWave Therapeutics, Inc. (Part of J&J Medical Devices Division)

NET0030
Pilot Phase 1 Study of Peroperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastro-enteropancreatic Neuroendocrine Tumors
PI: Visser
Sponsor: Stanford University

NET0032
Phase III Peptide Receptor Radionuclide Tx w/ Lu-Edotreotide vs SoC in SSTR+ Neuroendocrine Tumors
PI: Igaru
Sponsor: ITM Solucin GmbH

1st Priority

NET0036
Phase Ib/II RYZ101 vs Standard of Care Therapy in Inoperable Advanced Somatostatin Receptor Expressing (SSTR+) Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that Have Progressed Following Prior 177Lu-Labelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1)
PI: Franc
Sponsor: RayzeBio, Inc.

ECOG-ACRIN-A021602
Phase IIICabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus
PI: Shahgulta
Sponsor: ECOG-ACRIN

NET0033
Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Palisotin Treatment in Carcinoid Syndrome
PI: Shaheen
Sponsor: Cinetics Pharmaceuticals, Inc.